Implications of circulating chromogranin A in prostate cancer

References

• Di Sant'Agnese PA, Cockett AT. Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78: 357–61
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Falkmer S, Falt K, Grimelius L. The course of neuroendocrine differentiation in prostatic carcinomas. An immunohistochemical study testing chromogranin A as an “endocrine marker”. Pathol Res Pract 1989; 185: 373–80
   PubMed Web of Science ®Google Scholar
• Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991; 19: 91–8
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA, Wadstrom LB, Alumets J, Falker S, Grimelius L. Peptide hormone and serotonin-immunoreactive cells in normal and hyperplastic prostate glands. Pathol Res Pract 1986; 181: 675–83
   PubMed Web of Science ®Google Scholar
• Aprikian A, Han K, Guy L, Landry F, Begin LR, Chevalier S. Neuroendocrine differentiation and the bombesin/gastrin-releasing peptide family of neuropeptides in the progression of human prostate cancer. Prostate Suppl 1998; 8: 52–61
   PubMedGoogle Scholar
• Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996; 74: 910–16
   PubMed Web of Science ®Google Scholar
• Di Sant'Agnese PA, de Mesy Jensen K. Somatostatin and/or somatostatin-like immunoreactive endocrine-paracrine cells in the human prostate gland. Arch Pathol Lab Med 1984; 108: 693–6
   PubMed Web of Science ®Google Scholar
• Di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: recent findings and new concepts. Cancer (Suppl) 1995; 75: 1850–9
   Web of Science ®Google Scholar
• Di Sant'Agnese PA. Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects Urology 1998;51((5A Suppl)):121–4.
   PubMed Web of Science ®Google Scholar
• Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503–19
   PubMed Web of Science ®Google Scholar
• Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, et al. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001; 12(Suppl 2)159–64
   PubMed Web of Science ®Google Scholar
• Angelsen A, Syversen U, Syridsberg M, Haugen OA, Mjolnerod OK, Waldum HL. Use of neuroendocrine serum markers in the follow-up of patients with cancer of the prostate. Prostate 1997; 31: 110–7
   PubMed Web of Science ®Google Scholar
• Deftos LJ, Nakada S, Burton DW, diSant'Agnese PA, Cockett AT, Abrahamsson PA. Immunoassay and immunohistology studies of chromogranin A as a neuroendocrine marker in patients with carcinoma of the prostate. Urology 1996; 48: 58–62
   PubMed Web of Science ®Google Scholar
• Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiyama N, Ito H. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512–5
   PubMed Web of Science ®Google Scholar
• Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto Y. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586–92
   PubMed Web of Science ®Google Scholar
• Whitmore WF Jr. Natural history and staging of prostate cancer Urol Clin North Am 1984;11: 205–20.
   PubMed Web of Science ®Google Scholar
• Cussenot O, Villette JM, Valeri A, Cariou G, Desgrandchamps F, Cortesse A, et al. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 1996; 155: 1340–3
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Mosca A, Gorzegno G, Bollito E, Mari M, et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Ann Oncol 2001; 12(Suppl 2)153–7
   Web of Science ®Google Scholar
• Kimura N, Hoshi S, Takahashi M, Takeha S, Shizawa S, Nagura H. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. J Urol 1997; 157: 565–8
   PubMed Web of Science ®Google Scholar
• Kadmon D, Thompson TC, Lynch GR, Scardino PT. Elevated plasma chromogranin-A concentrations in prostatic carcinoma. J Urol 1991; 146: 358–61
   PubMed Web of Science ®Google Scholar
• Sciarra A, Di Silverio F. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004; 63: 523–7
   PubMed Web of Science ®Google Scholar
• Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Lucera R, et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55: 168–79
   PubMed Web of Science ®Google Scholar
• Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, et al. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Res 2000; 60: 741–8
   PubMed Web of Science ®Google Scholar
• Sciarra A, Voria G, Monti S, Mazzone L, Mariotti G, Pozza M, et al. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A. Prostate 2004; 58: 421–8
   PubMed Web of Science ®Google Scholar
• Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M, et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590–7
   PubMed Web of Science ®Google Scholar
• Ferrero-Pous M, Hersant AM, Pecking A, Bresard-Leroy M, Pichon MF. Serum chromogranin-A in advanced prostate cancer. BJU Int 2001; 88: 790–6
   PubMed Web of Science ®Google Scholar